Clinical Trial Update: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial comparing otilimab (GSK3196165) to placebo and sarilumab in moderately to severely active rheumatoid arthritis patients with inadequate response t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GSK3196165 (GSK3196165)
• Sarilumab (sarilumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2023-07-17